INVENTIVA (EPA:IVA) | WebDisclosure

BRIEF

published on 04/15/2025 at 22:05, 1 month 28 days ago

Inventiva Files 2024 Financial Documents with Regulatory Agencies

Biopharmaceutical Regulatory Filing Inventiva MASH 2024 Financials
PRESS RELEASE

published on 04/15/2025 at 22:00, 1 month 28 days ago

Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2024 et de son Rapport Annuel 2024 (« Form 20-F »)
Inventiva dépose son Document d’Enregistrement Universel 2024 et son Rapport Annuel 2024 (Form 20-F) auprès de l’AMF et de la SEC. Les documents sont disponibles sur les sites internet respectifs

AMF SEC Inventiva Rapport Annuel 2024 Document D'Enregistrement Universel 2024
PRESS RELEASE

published on 04/15/2025 at 22:00, 1 month 28 days ago

Inventiva announces filing of its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F
Inventiva files its 2024 Universal Registration Document and 2024 Annual Report on Form 20-F with the AMF and SEC. Documents accessible on Inventiva's website and regulatory authorities' sites

2024 Form 20-F Registration Document Clinical-Stage Biopharmaceutical Inventiva
BRIEF

published on 03/26/2025 at 21:05, 2 months 18 days ago

Inventiva unveils its 2024 financial results and strategic projects

Strategic Reorganization 2024 Financial Results Research & Development Lanifibranor Structured Financing
BRIEF

published on 03/26/2025 at 21:05, 2 months 18 days ago

Inventiva dévoile ses résultats financiers 2024 et ses projets stratégiques

Réorganisation Stratégique Résultats Financiers 2024 Recherche & Développement Lanifibranor Financement Structuré
PRESS RELEASE

published on 03/26/2025 at 21:00, 2 months 18 days ago

Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité
Inventiva publie ses résultats financiers annuels 2024 et fait le point sur son activité avec chiffre d'affaires de 9,2 millions d'euros, trésorerie à 96,6 millions d'euros et levée de 116 millions d'euros

Chiffre D'affaires Résultats Financiers Financement Trésorerie Inventiva
PRESS RELEASE

published on 03/26/2025 at 21:00, 2 months 18 days ago

Inventiva reports its 2024 full year results and provides a business update
Inventiva reports its 2024 full year financial results with revenues of €9.2 million, cash equivalents of €96.6 million and a structured financing of up to €348 million. Significant progress in the NATiV3 Phase 3 trial of lanifibranor for MASH. Pipeline prioritization plan presented

Revenues Financial Results Inventiva Cash Equivalents NATiV3 Phase 3 Trial
BRIEF

published on 03/19/2025 at 21:05, 2 months 25 days ago

Inventiva Announces 2024 Full-Year Financial Results Schedule

Financial Results Webcast Inventiva Lanifibranor MASH Treatment
BRIEF

published on 03/19/2025 at 21:05, 2 months 25 days ago

Inventiva annonce le calendrier des résultats financiers annuels 2024

Résultats Financiers Webcast Inventiva Lanifibranor Traitement MASH
PRESS RELEASE

published on 03/19/2025 at 21:00, 2 months 25 days ago

Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
Inventiva schedules 2024 Full-Year Financial Results presentation on March 27, 2025. Webcast available. Company focused on small molecule therapies for MASH

Presentation 2024 Financial Results Inventiva MASH Small Molecule Therapies

Published on 06/14/2025 at 02:00, 59 minutes ago

Battery X Metals Validates Provisional Patent Applications Filed with the United States Patent and Trademark Office Through Successful Real-World Trials of Next-Generation Lithium-Ion Battery Rebalancing Machine
Published on 06/14/2025 at 01:52, 1 hour 7 minutes ago

Avino Renews ATM Equity Program
Published on 06/14/2025 at 01:05, 1 hour 54 minutes ago

Diamcor Receives Section 244 Notice from Tiffany & Co.
Published on 06/14/2025 at 00:15, 2 hours 44 minutes ago

Carbeeza Announces Settlement Agreement
Published on 06/14/2025 at 00:00, 2 hours 59 minutes ago

Onco-Innovations Engages the University of Alberta and Cross Cancer Institute to Expand PNKP Inhibitor Research into Hard-to-Treat Cancers

View all ACCESSWIRE

Published on 06/13/2025 at 19:10, 7 hours 49 minutes ago

Allane Mobility Group records growth in operating business in 2024
Published on 06/13/2025 at 18:47, 8 hours 12 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/13/2025 at 18:47, 8 hours 12 minutes ago

Funding Circle Holdings plc: HOL-Holdings in Company - AMENDED
Published on 06/13/2025 at 18:42, 8 hours 17 minutes ago

Funding Circle Holdings plc: HOL-Holdings in Company - AMENDED
Published on 06/13/2025 at 18:00, 8 hours 59 minutes ago

BOA CONCEPT: Mise à disposition des documents préparatoires de l’Assemblée Générale du 26 juin 2025

View all EQS

Published on 06/13/2025 at 18:07, 8 hours 52 minutes ago

Déclaration des transactions sur actions propres réalisées du 2 juin au 6 juin 2025
Published on 06/13/2025 at 18:07, 8 hours 52 minutes ago

Disclosure of trading in own shares between June 2nd and 6th, 2025
Published on 06/13/2025 at 17:45, 9 hours 14 minutes ago

STEF : Droits de vote au 31-05-2025
Published on 06/13/2025 at 09:55, 17 hours 4 minutes ago

Déclaration d'actions et de droits de vote au 31.05.2025
Published on 06/13/2025 at 09:33, 17 hours 26 minutes ago

Combined General Meeting, June 12, 2025

View all LES ECHOS COMFI WIRE

News